MEDYTOX revenue for the last year amounted to 221.00 B KRW, the most of which — 217.16 B KRW — came from its highest performing source at the moment, Biopharmaceutical Products, the year earlier bringing 191.46 B KRW. The greatest contribution to the revenue figure was made by South Korea — last year it brought MEDYTOX 79.82 B KRW, and the year before that — 66.70 B KRW.